Tivic Health shares surge 20.42% intraday after securing BARDA meeting and showcasing Entolimod data for radiation injuries.

Tivic Health surged 20.42% intraday after announcing a pivotal BARDA meeting for Entolimod’s development to address acute radiation syndrome. The session highlighted the drug’s FDA Fast Track and Orphan Drug designations, potential government partnerships, and clinical promise in radiation injury. Additionally, a Techwatch meeting showcased Entolimod’s data on radiation-induced injury, reinforcing its therapeutic potential. These developments, emphasizing regulatory and commercial milestones, aligned with the stock’s sharp intraday rally.